{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ABT/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T12:16:56.238Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":7013,"canonical_name":"ABBOTT LABORATORIES","cik":"0000001800","uei":null,"lei":null,"duns":null,"ticker":"ABT"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"court":3,"sec":22,"doj":2},"count":27,"timeline":[{"ts":"2026-10-14","kind":"court.docket","reporter":"ilnd","title":"Crow v. ABBOTT LABORATORIES","security_title":"365 Personal Inj. Prod. Liability","excerpt":"28:1332 Diversity-Product Liability","accession_number":"1:26-cv-12598","product_type":"Edmond E-Min Chang","importance":45},{"ts":"2026-10-13","kind":"court.docket","reporter":"ilnd","title":"Nix v. ABBOTT LABORATORIES","security_title":"367 Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability","excerpt":"28:1332 Diversity-(Citizenship)","accession_number":"1:26-cv-12542","product_type":null,"importance":45},{"ts":"2026-10-12","kind":"court.docket","reporter":"ilnd","title":"Thompson v. ABBOTT LABORATORIES","security_title":"367 Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability","excerpt":"28:1332 Diversity-Account Receivable","accession_number":"1:26-cv-12486","product_type":null,"importance":45},{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — ABBOTT LABORATORIES — 2026-10-02","url_slug":"/sec/cik-0000001800/4/0001104659-26-113285","accession_number":"0001104659-26-113285","importance":30},{"ts":"2026-10-02","kind":"sec.filing","form_type":"4","title":"4 — ABBOTT LABORATORIES — 2026-10-02","url_slug":"/sec/cik-0000001800/4/0001104659-26-113287","accession_number":"0001104659-26-113287","importance":30},{"ts":"2026-09-14","kind":"doj.press","reporter":"Civil Division; Office of the Associate Attorney General","title":"Abbott Agrees to Pay Over $384M to Settle Allegations Related to Contaminated Infant Formula","security_title":null,"excerpt":"Abbott Laboratories (Abbott), an Illinois-based healthcare company that manufactures and sells infant formula and nutritional therapy products, has agreed to pay $384,999,040 to resolve allegations that it caused false claims to be submitted between ","accession_number":"26-1049","importance":80},{"ts":"2026-09-14","kind":"doj.press","reporter":"USAO - Michigan, Western","title":"Abbott Agrees to Pay Over $384 Million to Settle False Claims Act Allegations Related to Powder Infant Formula and Nutritional Therapy Products","security_title":"Fraud","excerpt":null,"accession_number":null,"importance":80},{"ts":"2026-09-03","kind":"sec.filing","form_type":"4","title":"4 — ABBOTT LABORATORIES — 2026-09-03","url_slug":"/sec/cik-0000001800/4/0001805099-26-000008","accession_number":"0001805099-26-000008","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"8-K","title":"8-K — ABBOTT LABORATORIES — 2026-08-20","url_slug":"/sec/cik-0000001800/8-k/0001104659-26-099247","accession_number":"0001104659-26-099247","importance":35},{"ts":"2026-08-13","kind":"sec.filing","form_type":"4","title":"4 — ABBOTT LABORATORIES — 2026-08-13","url_slug":"/sec/cik-0000001800/4/0001867666-26-000013","accession_number":"0001867666-26-000013","importance":30},{"ts":"2026-08-11","kind":"sec.form144","reporter":"Louis H. Morrone","title":"Officer","shares":5850,"usd_value":642506,"security_title":"Common","approx_sale_date":"2026-08-11","accession_number":"0001867666-26-000011","importance":40.1285012},{"ts":"2026-08-11","kind":"sec.filing","form_type":"144","title":"144 — ABBOTT LABORATORIES — 2026-08-11","url_slug":"/sec/cik-0000001800/144/0001867666-26-000011","accession_number":"0001867666-26-000011","importance":30},{"ts":"2026-07-28","kind":"sec.filing","form_type":"10-Q","title":"10-Q — ABBOTT LABORATORIES — 2026-07-28","url_slug":"/sec/cik-0000001800/10-q/0001628280-26-050134","accession_number":"0001628280-26-050134","importance":45},{"ts":"2026-07-16","kind":"sec.filing","form_type":"8-K","title":"8-K — ABBOTT LABORATORIES — 2026-07-16","url_slug":"/sec/cik-0000001800/8-k/0001628280-26-048377","accession_number":"0001628280-26-048377","importance":35},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — ABBOTT LABORATORIES — 2026-07-01","url_slug":"/sec/cik-0000001800/4/0002102715-26-000006","accession_number":"0002102715-26-000006","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — ABBOTT LABORATORIES — 2026-07-01","url_slug":"/sec/cik-0000001800/4/0001867666-26-000009","accession_number":"0001867666-26-000009","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — ABBOTT LABORATORIES — 2026-07-01","url_slug":"/sec/cik-0000001800/4/0001879701-26-000008","accession_number":"0001879701-26-000008","importance":30},{"ts":"2026-06-30","kind":"sec.insider.f","reporter":"Morrone Louis H.","title":"EXECUTIVE VICE PRESIDENT","shares":269,"price_per_share":92.71,"usd_value":24939,"security_title":"Common shares without par value","importance":15.02493899},{"ts":"2026-06-29","kind":"sec.filing","form_type":"4","title":"4 — ABBOTT LABORATORIES — 2026-06-29","url_slug":"/sec/cik-0000001800/4/0002075371-26-000009","accession_number":"0002075371-26-000009","importance":30},{"ts":"2026-06-27","kind":"sec.insider.f","reporter":"Cushman Elizabeth C.","title":"EVP, GC AND SECRETARY","shares":560,"price_per_share":94.12,"usd_value":52707,"security_title":"Common shares without par value","importance":15.0527072},{"ts":"2026-06-18","kind":"sec.filing","form_type":"11-K","title":"11-K — ABBOTT LABORATORIES — 2026-06-18","url_slug":"/sec/cik-0000001800/11-k/0001104659-26-075724","accession_number":"0001104659-26-075724","importance":30},{"ts":"2026-05-15","kind":"sec.form144","reporter":"Robert  J. Alpern","title":"Retired Director","shares":7587,"usd_value":646791,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001448074-26-000012","importance":40.1293582},{"ts":"2026-05-07","kind":"sec.insider.p","reporter":"Stratton John G","title":"","shares":2000,"price_per_share":86.82,"usd_value":173640,"security_title":"Common shares without par value","importance":50.17364},{"ts":"2026-04-27","kind":"sec.filing","form_type":"8-K","title":"8-K — ABBOTT LABORATORIES — 2026-04-27","url_slug":"/sec/cik-0000001800/8-k/0001104659-26-049434","accession_number":"0001104659-26-049434","importance":35},{"ts":"2026-04-27","kind":"sec.filing","form_type":"4","title":"4 — ABBOTT LABORATORIES — 2026-04-27","url_slug":"/sec/cik-0000001800/4/0001805099-26-000006","accession_number":"0001805099-26-000006","importance":30},{"ts":"2026-04-23","kind":"sec.insider.p","reporter":"Boudreau Philip P","title":"EVP AND CFO","shares":2200,"price_per_share":91.5,"usd_value":201300,"security_title":"Common shares without par value","importance":50.2013},{"ts":"2026-04-23","kind":"sec.insider.i","reporter":"Boudreau Philip P","title":"EVP AND CFO","shares":8909,"price_per_share":92.04,"usd_value":819984,"security_title":"Common shares without par value","importance":15.81998436}]}